investors

Press Releases
Date Title and Summary View
July 25, 2016 LOS ANGELES, July 25, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly diagnosed glioblastoma and the phase 1 trial of ICT-121 for recurrent glioblastoma. In the I...
June 7, 2016 LOS ANGELES, June 7, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company's lead cancer immunotherapy product candidate, in newly diagnosed glioblastoma. ICT-107 is a patient-specific, dendritic c...
May 23, 2016 LOS ANGELES, May 23, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday, June 2, 2016 at 2:00 pm ET at the Grand Hyatt hotel, New Y...
May 12, 2016 LOS ANGELES, May 12, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the first quarter of 2016.  Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: "We continue to make progress in all aspects of implementing our ICT-107 registration trial in...
May 6, 2016 LOS ANGELES, May 6, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company has received approval from regulatory authorities in Canada, the United Kingdom and the Netherlands to initiate the ICT-107 Phase 3 registration trial in patients with newly diagnosed glioblastoma. Patient ...
May 4, 2016 LOS ANGELES, May 4, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2016 financial results on Thursday, May 12, 2016. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the first quarter 2016 financial resu...
March 30, 2016 LOS ANGELES, March 30, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for 2015.  Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: "We made important progress in advancing the company in 2015.  In particular, we designed and began executing wha...
March 29, 2016 LOS ANGELES, March 29, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for 2015 on Wednesday, March 30, 2016. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the 2015 financial results and provide a ...
March 7, 2016 LOS ANGELES, March 7, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 28th Annual ROTH Conference on Wednesday, March 16, 2016 at 8:30 am PT, at the Ritz-Carlton Hotel...
February 16, 2016 LOS ANGELES, Feb. 16, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell receptors (TCRs) developed in the laboratory of Prof. Mark Davi...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase
Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved